Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson's disease

Movement Disorders

Volumn 29, Issue 8, 2014, Pages 1028-1034

  Hauser, Robert A ^a   Silver, Dee ^b   Choudhry, Azhar ^c   Eyal, Eli ^d   Isaacson, Stuart ^e  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b Coastal Neurological Medical Group ^*  (United States)

^c Teva Pharmaceuticals   (United States)

^d TEVA PHARMACEUTICALS   (Israel)

^e Parkinson's Disease and Movement Disorders Center of Boca Raton   (United States)

Author keywords

Dopamine agonists; Parkinson's disease; Pramipexole; Rasagiline; Ropinirole; Treatment

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; INDAN DERIVATIVE; NEUROPROTECTIVE AGENT; RASAGILINE;

AGED; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; OUTCOME ASSESSMENT; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIAL; SEVERITY OF ILLNESS INDEX; TIME; UNITED STATES;

AGED; DOPAMINE AGONISTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INDANS; MALE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; OUTCOME ASSESSMENT (HEALTH CARE); PARKINSON DISEASE; SEVERITY OF ILLNESS INDEX; TIME FACTORS; UNITED STATES;

EID: 84904436776     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25877     Document Type: Article

References (28)

1. Holloway RG, Shoulson I, Fahn S, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004;61:1044-1053.
2. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000;342:1484-1491.
3. Antonini A, Tolosa E, Mizuno Y, Yamamoto M, Poewe WH. A reassessment of risks and benefits of dopamine agonists in Parkinson's disease. Lancet Neurol 2009;8:929-937.
4. Weintraub D, Siderowf AD, Potenza MN, et al. Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol 2006;63:969-973.
5. Perez-Lloret S, Rey MV, Fabre N, et al. Prevalence and pharmacological factors associated with impulse-control disorder symptoms in patients with Parkinson disease. Clin Neuropharmacol 2012;35:261-265.
6. Hauser RA, McDermott MP, Messing S. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. Arch Neurol 2006;63:1756-1760.
7. Olanow CW, Kieburtz K, Rascol O, et al. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease. Mov Disord 2013;28:1064-1071.
8. Youdim MB, Edmondson D, Tipton KF. The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci 2006;7:295-309.
9. Fahn S, Elton RL. Unified Parkinson's Disease Rating Scale. Recent developments in Parkinson's disease: MacMillan Healthcare Information, 1987:153-164.
10. Doty RL, Marcus A, Lee WW. Development of the 12-item cross-cultural smell identification test (CC-SIT). Laryngoscope 1996;106:353-356.
11. Marinus J, Visser M, Verwey NA, et al. Assessment of cognition in Parkinson's disease. Neurology 2003;61:1222-1228.
12. Peto V, Jenkinson C, Fitzpatrick R. PDQ-39: a review of the development, validation and application of a Parkinson's disease quality of life questionnaire and its associated measures. J Neurol 1998;245[Suppl 1]:S10-S14.
13. Guy W. Clinical global impressions. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: Department of Health, Education, and Welfare, Washington, DC, 1976:218-222.
14. Marinus J, Visser M, van Hilten JJ, Lammers GJ, Stiggelbout AM. Assessment of sleep and sleepiness in Parkinson disease. Sleep 2003;26:1049-1054.
15. Schrag A, Sampaio C, Counsell N, Poewe W. Minimal clinically important change on the unified Parkinson's disease rating scale. Mov Disord 2006;21:1200-1207.
16. Shulman LM, Gruber-Baldini AL, Anderson KE, Fishman PS, Reich SG, Weiner WJ. The clinically important difference on the unified Parkinson's disease rating scale. Arch Neurol 2010;67:64-70.
17. Hauser RA, Auinger P. Determination of minimal clinically important change in early and advanced Parkinson's disease. Mov Disord 2011;26:813-818.
18. Rascol O. Defining a minimal clinically relevant difference for the unified Parkinson's rating scale: an important but still unmet need. Mov Disord 2006;21:1059-1061.
19. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol 2002;59:1937-1943.
20. Chen PC, Lao CL, Chen JC. The D(3) dopamine receptor inhibits dopamine release in PC-12/hD3 cells by autoreceptor signaling via PP-2B, CK1, and Cdk-5. J Neurochem 2009;110:1180-1190.
21. Phillips PE, Hancock PJ, Stamford JA. Time window of autoreceptor-mediated inhibition of limbic and striatal dopamine release. Synapse 2002;44:15-22.
22. Coldwell MC, Boyfield I, Brown T, Hagan JJ, Middlemiss DN. Comparison of the functional potencies of ropinirole and other dopamine receptor agonists at human D2(long), D3 and D4.4 receptors expressed in Chinese hamster ovary cells. Br J Pharmacol 1999;127:1696-1702.
23. Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 2005;62:241-248.
24. Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005;365:947-954.
25. Elmer LW. Rasagiline adjunct therapy in patients with Parkinson's disease: post hoc analyses of the PRESTO and LARGO trials. Parkinsonism Relat Disord 2013;19:930-936.
26. Petit GH, Berkovich E, Hickery M, Kallunki P, Fog K, Fitzer-Attas C, Brundin P. Rasagiline ameliorates olfactory deficits in an alpha-synuclein mouse model of Parkinson's disease. PloS One 2013;8:e60691.
27. Alvarez MV, Grogan PM. Hyposmia in Parkinson's disease. Psychiatry Clin Neurosci 2012;66:370.
28. Haehner A, Hummel T, Wolz M, Klingelhöfer L, Fauser M, Storch A, Reichmann H. Effects of rasagiline on olfactory function in patients with Parkinson's disease. Mov Disord. 2013 Nov 4. Doi: 10.1002/mds.25661.